Inhibition of the PI3K/AKT/mTOR pathway activates autophagy and compensatory Ras/Raf/MEK/ERK signalling in prostate cancer

Butler, Dominika E., Marlein, Christopher, Walker, Hannah F., Frame, Fiona M., Mann, Vincent M., Simms, Matthew S., Davies, Barry R., Collins, Anne T. and Maitland, Norman J. (2017) Inhibition of the PI3K/AKT/mTOR pathway activates autophagy and compensatory Ras/Raf/MEK/ERK signalling in prostate cancer. Oncotarget, 8. pp. 56698-56713. ISSN 1949-2553

Preview

PDF (Published manuscript) - Published Version Available under License Creative Commons Attribution. Download (4MB) | Preview

Abstract

The PI3K/AKT/mTOR pathway is frequently activated in advanced prostate cancer, due to loss of the tumour suppressor PTEN, and is an important axis for drug development. We have assessed the molecular and functional consequences of pathway blockade by inhibiting AKT and mTOR kinases either in combination or as individual drug treatments. In established prostate cancer cell lines, a decrease in cell viability and in phospho-biomarker expression was observed. Although apoptosis was not induced, a G1 growth arrest was observed in PTEN null LNCaP cells, but not in BPH1 or PC3 cells. In contrast, when the AKT inhibitor AZD7328 was applied to patient-derived prostate cultures that retained expression of PTEN, activation of a compensatory Ras/MEK/ERK pathway was observed. Moreover, whilst autophagy was induced following treatment with AZD7328, cell viability was less affected in the patient-derived cultures than in cell lines. Surprisingly, treatment with a combination of both AZD7328 and two separate MEK1/2 inhibitors further enhanced phosphorylation of ERK1/2 in primary prostate cultures. However, it also induced irreversible growth arrest and senescence. Ex vivo treatment of a patient-derived xenograft (PDX) of prostate cancer with a combination of AZD7328 and the mTOR inhibitor KU-0063794, significantly reduced tumour frequency upon re-engraftment of tumour cells. The results demonstrate that single agent targeting of the PI3K/AKT/mTOR pathway triggers activation of the Ras/MEK/ERK compensatory pathway in near-patient samples. Therefore, blockade of one pathway is insufficient to treat prostate cancer in man.

Item Type:	Article
Uncontrolled Keywords:	prostate cancer,akt,mtor,ras,mapk signalling,autophagy,sdg 3 - good health and well-being ,/dk/atira/pure/sustainabledevelopmentgoals/good_health_and_well_being
Faculty \ School:	Faculty of Medicine and Health Sciences > Norwich Medical School
Related URLs:	http://www.oncotarget.com/fulltext/18082
Depositing User:	Pure Connector
Date Deposited:	03 Oct 2017 05:10
Last Modified:	21 Oct 2022 16:32
URI:	https://ueaeprints.uea.ac.uk/id/eprint/65015
DOI:	10.18632/oncotarget.18082

Downloads

Actions (login required)

View Item